Insurance Curator NEW YORK — Global life insurance providers and reinsurers are fundamentally restructuring their mortality and morbidity models this year as the rapid adoption of GLP-1 receptor agonists demonstrates a significant shift in the risk profile of policyholders with obesity-related conditions.
The integration of drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) into standard medical care is forcing underwriters to move beyond traditional Body Mass Index (BMI) metrics. Instead, they are focusing on the pharmaceutical mitigation of comorbidities such as cardiovascular disease, Type 2 diabetes, and obstructive sleep apnea. This shift, which gained momentum in late 2024 and early 2025 following a series of landmark clinical trials, marks one of the most significant changes to life insurance risk assessment in the post-pandemic era.
“We are witnessing a pivot from viewing obesity as a static risk factor to viewing it as a treatable condition with measurable outcomes,” said Dr. Marianne Cumming, a medical consultant for several North American life insurers. “The mortality modeling that previously penalized a high BMI is being refined to account for the protective cardiovascular effects these medications provide.”
A New Framework for Mortality Modeling
For decades, the life insurance industry has relied on BMI as a primary proxy for mortality risk. High BMI scores typically triggered higher premiums or outright denials due to the associated risks of heart failure, stroke, and metabolic syndrome. However, recent data from the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events (MACE) among non-diabetic patients using semaglutide, has provided the actuarial evidence necessary to update these models.
Reinsurance Group of America (RGA), one of the world’s largest life reinsurers, has been at the forefront of analyzing how these drugs affect long-term survival. In a recent research briefing, RGA analysts noted that while obesity remains a concern, the "comorbidity-sparing" effects of GLP-1s could lead to a downward adjustment in projected mortality rates for certain demographics.
“The question is no longer just how much a person weighs, but how effectively their metabolic health is being managed,” said Robert Jenkins, a senior actuary specializing in mortality trends. “Our models are beginning to reflect that a patient on a sustained GLP-1 regimen may have a risk profile closer to a person with a lower BMI who is not on the medication.”
Impact on Obesity-Related Comorbidities
The underwriting shift is most pronounced in three specific areas:
1. Cardiovascular Risk:
In March 2024, the FDA approved a new indication for Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity. This regulatory milestone allowed life insurers to categorize GLP-1 prescriptions not merely as "lifestyle drugs," but as preventative cardiovascular therapy, similar to statins.
2. Type 2 Diabetes Management:
While GLP-1s have long been used for diabetes, their increased efficacy in weight loss has led to higher rates of "clinical remission" for Type 2 diabetes. Underwriters are now evaluating whether a policyholder in remission should be rated as a diabetic or as a standard risk, provided they maintain their medication adherence.
3. Kidney Disease and Sleep Apnea:
Recent clinical data, including the FLOW trial, showed that semaglutide reduced the risk of kidney disease progression by 24%. Additionally, the SURMOUNT-OSA trial demonstrated that tirzepatide significantly reduced the severity of obstructive sleep apnea. Because both chronic kidney disease and sleep apnea are high-weighted factors in life insurance pricing, these improvements are leading to more favorable ratings for applicants.
The Challenge of Adherence and "Rebound" Risk
Despite the clinical optimism, insurers remain cautious regarding the long-term sustainability of these health improvements. Actuarial skepticism centers on two primary factors: cost-related access and medication adherence.
Current data suggests a high "quit rate" for GLP-1 medications due to gastrointestinal side effects or loss of insurance coverage. When a patient stops taking the medication, weight regain and the return of comorbid risks are common.
“From an underwriting perspective, we have to ask: 'Is this a permanent change in the applicant's health, or a temporary one?'” Jenkins said. “If a policyholder stops the drug three years into a 20-year term policy, the mortality benefit vanishes. This makes long-term adherence data the ‘holy grail’ for current risk assessment.”
To mitigate this, some insurers are exploring "dynamic underwriting" or "wellness-linked policies." Under these structures, policyholders might receive premium discounts that are contingent on proof of continued treatment or the maintenance of health markers like HbA1c levels and blood pressure.
Economic and Market Implications
The high cost of GLP-1 drugs—often exceeding $1,000 per month without insurance—has created a socio-economic divide in the risk pool. Currently, applicants who can afford these medications tend to belong to higher socio-economic tiers, which already experience lower mortality rates.
According to a report by Swiss Re, the "GLP-1 effect" could potentially widen the gap in life expectancy between different income groups. This poses a challenge for group life insurance providers who manage broad employee populations with varying levels of drug access.
"We are watching the 'Ozempic divide' very closely," said Samantha Miller, a life insurance market analyst. "If only the wealthiest applicants have access to these life-extending drugs, the industry must be careful not to create a two-tiered system of insurability."
Future Outlook
As more competitors enter the market and drug prices potentially decrease with the introduction of oral versions and generic alternatives, the impact on underwriting is expected to normalize.
For now, the industry is moving toward a "wait and see" approach for the most aggressive premium reductions, while simultaneously easing the "table ratings" (extra premiums) for obese applicants who can demonstrate at least 12 to 24 months of successful GLP-1 therapy.
“The science is ahead of the actuarial tables right now,” Dr. Cumming said. “But the direction is clear. We are moving toward a more nuanced, pharmaceutical-aware version of risk management that recognizes obesity as a manageable chronic condition rather than a permanent mortality burden.”
Industry experts expect the next two years to bring a wave of new policy filings with state regulators that formally incorporate GLP-1 usage into preferred-risk criteria, potentially lowering the cost of life insurance for millions of Americans currently classified as high-risk.